Somatostatin as an Active Substance of Enteroendocrine Cells in the Canine Digestive Tract in Physiological Conditions and during Inflammatory Bowel Disease

Abstract

The aim of the present investigation is to examine the changes in the number of somatostatin-like immunoreactive (SOM-LI) enteroendocrine cells in various parts of the canine gastrointestinal (GI) tract during canine inflammatory bowel disease (IBD). The distribution of SOM-LI enteroendocrine cells was studied using the double-labeling immunofluorescence technique with antisera against chromogranin A (CgA; used here as a marker of enteroendocrine cells) and somatostatin (SOM). Evaluation of the number of CgA-positive cells, which also contained SOM in the mucosal layer of canine stomach, duodenum, jejunum and descending colon was based on the counting of such cells per unit area (0.1 mm2). In physiological conditions, the number of SOM-LI enteroendocrine cells has been shown to constitute 5.30±2.07 in the stomach, 2.23±0.56 in the duodenum, 1.86±0.48 in the jejunum and 1.19±0.36 in the descending colon. Canine IBD caused an increase in the number of cells studied in the stomach (to 9.55±1.46) and the jejunum (to 3.84±1.16), while the changes observed in the duodenum and the descending colon have not been statistically significant. The obtained results suggest that SOM-LI enteroendocrine cells, as well as somatostatin, may be involved in pathological processes during canine IBD. Moreover, this study can be treated as the first step of application of SOM and/or its analogues in the treatment of canine IBD in the future.